Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (324)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00645385 | Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.(Gliadel-MRS) | withdrawn | — | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03176160 | LITT Palliative Treatment for Patients With Malignant Gliomas | withdrawn | — | 0 | Duke University |
| 1 |
| Feb 27, 2019 |
| clinicaltrials |
| NCT02540135 | Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT03275558 | Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma | withdrawn | Phase 1 | 0 | Center Trials & TreatmentOTHER | 2 | Jul 19, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02590497 | Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 31, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 17, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02194452 | Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors | withdrawn | N/A | 0 | Sue O'DorisioOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | withdrawn | Phase 4 | 0 | Jun ZhuOTHER | 1 | Dec 30, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | withdrawn | Phase 2 | 0 | Constantinos HadjipanayisOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT01830101 | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | withdrawn | Phase 3 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00703859 | Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 0 | Feb 3, 2016 | clinicaltrials |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 6, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | withdrawn | Phase 1 | 0 | Medical University of South CarolinaOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT01711580 | Re-irradiation of High Grade Gliomas: a Quality of Life Study | withdrawn | — | 0 | Maastricht Radiation OncologyOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT01769911 | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2015 | clinicaltrials |
| NCT01317212 | Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme | withdrawn | Phase 1 | 0 | North Bristol NHS TrustOTHER | 1 | Apr 17, 2015 | clinicaltrials |
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT01169415 | Effects of Steroid Tapering on Functional Capacity and Neurocognition | withdrawn | N/A | 0 | Duke UniversityOTHER | 0 | May 19, 2014 | clinicaltrials |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens(PERFORMANCE) | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Jan 14, 2014 | clinicaltrials |
| NCT01115036 | A Panobinostat Presurgery(CLBH589C) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00801918 | Denileukine Diftitox for Relapsed ALCL | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00797940 | Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)(CLARITY-1) | withdrawn | Phase 2 | 0 | Sophiris Bio CorpINDUSTRY | 0 | Dec 3, 2012 | clinicaltrials |
| NCT00734864 | Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | withdrawn | Phase 1 | 0 | Annick DesjardinsOTHER | 1 | Nov 21, 2012 | clinicaltrials |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 20, 2012 | clinicaltrials |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Dec 20, 2011 | clinicaltrials |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | withdrawn | Phase 2 | 5 | National Taiwan University HospitalOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme | withdrawn | Phase 1 | 30 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | May 20, 2009 | clinicaltrials |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme | withdrawn | Phase 3 | 323 | Xenova BiomedixINDUSTRY | 2 | Jan 7, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2019source: clinicaltrials